Bluejay Diagnostics shares rise 10.58% intraday after announcing 1-for-4 reverse stock split.

Bluejay Diagnostics surged 10.58% intraday trading following its announcement of a 1-for-4 reverse stock split, effective January 29, 2026. The move reduces outstanding shares from ~2.8 million to ~708,533, increasing per-share value and aligning with the company’s strategy to maintain Nasdaq listing requirements. The split, which adjusts prefunded warrants and equity awards proportionally, was widely perceived as a positive signal by investors, who interpreted the capital structure optimization as a step to enhance shareholder value. The stock’s sharp intraday rally directly correlated with the news, reflecting optimism about improved liquidity and reduced dilution risks post-split.